Investigational drug · Phase 2
LYS006
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Hidradenitis Suppurativa.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
4
Any phase or sponsor naming "LYS006"
First trial start
2019
Feb 27, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "LYS006", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hidradenitis Suppurativa
Approved drugs for the same conditions: Hidradenitis suppurativa · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "LYS006" as an intervention, largest first.
- Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis SuppurativaPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT03827798 · 248 participants · Start Feb 27, 2019 · Primary completion Dec 4, 2024
Drug: CFZ533; Placebo to CFZ533 and 9 more · For: Hidradenitis Suppurativa
Sites: Clearwater, Florida; Orange Park, Florida; Tampa, Florida · 36 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT03497897 · 66 participants · Start Sep 10, 2018 · Primary completion Feb 24, 2022
Drug: LYS006 20 mg; LYS006 2 mg and 1 more · For: Inflammatory Acne
Sites: Fremont, California; Santa Monica, California; Hialeah, Florida · 17 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT04147195 · 41 participants · Start Jun 4, 2020 · Primary completion Jan 6, 2022
Drug: LYS006; Tropifexor · For: Non-alcoholic Fatty Liver Disease; Nonalcoholic Steatohepatitis
Sites: Coronado, California; Los Angeles, California; Miami Lakes, Florida · 10 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT04074590 · 23 participants · Start Feb 3, 2020 · Primary completion Nov 7, 2022
Drug: LYS006; Placebo · For: Colitis, Ulcerative
Sites: Sofia, Bulgaria; Prague, Czechia; Zlín, Czechia · 9 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Clinical trial: A Phase 2 Randomised Platform Study to Assess Monotherapy and Combination Treatment Regimens in Metabolic Dysfunction-Associated Steatohepatitis.
Frias J, Schmouder R, Lawitz E, et al. · Aliment Pharmacol Ther 2026
- Optical Control of Leukotriene A4 Hydrolase Using Photoswitchable Inhibitors.
Zhou X, Wang S, Yang X, et al. · J Med Chem 2025
- LTA4H inhibitor LYS006: Clinical PK/PD and safety in a randomized phase I clinical trial.
Loesche C, Picard D, Van Hoorick B, et al. · Clin Transl Sci 2024
- Discovery of Amino Alcohols as Highly Potent, Selective, and Orally Efficacious Inhibitors of Leukotriene A4 Hydrolase.
Thoma G, Markert C, Lueoend R, et al. · J Med Chem 2023
- Human Pharmacokinetics of LYS006, an Oral Leukotriene A4 Hydrolase Inhibitor Displaying Target-Mediated Drug Disposition.
Poller B, Pearson D, Leuthold LA, et al. · Drug Metab Dispos 2022
- Discovery of LYS006, a Potent and Highly Selective Inhibitor of Leukotriene A4 Hydrolase.
Markert C, Thoma G, Srinivas H, et al. · J Med Chem 2021
Also in development for Hidradenitis Suppurativa
- ZasocitinibTAK- 279, NDI-034858Phase 317 trials
Takeda · Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease
- MK-7240PRA023, TulisokibartPhase 310 trials
Merck & Co. · Ulcerative Colitis, Psoriatic Arthritis, Crohn's Disease
- LutikizumabABT-981Phase 38 trials
AbbVie · Hidradenitis Suppurativa, Atopic Dermatitis, Rheumatoid Arthritis
- OlatorepatideHS-20094Phase 38 trials
Jiangsu Hansoh Pharmaceutical Co., Ltd. · Type 2 Diabetes, Overweight or Obesity, Overweight or Obesity Without Diabetes
- SonelokimabPhase 37 trials
MoonLake Immunotherapeutics AG · Hidradenitis Suppurativa, Arthritis, Psoriatic
- brivekimigSAR442970Phase 25 trials
Sanofi · Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion, Type 1 Diabetes Mellitus
- MAS825ArumakimigPhase 24 trials
Novartis · NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations, Still´s Disease, VEXAS Syndrome
- EltrekibartLY3041658Phase 22 trials
Eli Lilly · Ulcerative Colitis, Ulcerative Colitis Chronic, Hidradenitis Suppurativa
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novartis.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.